Description: Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Home Page: galectintherapeutics.com
GALT Technical Analysis
4960 Peachtree Industrial Boulevard
Norcross,
GA
30071
United States
Phone:
678 620 3186
Officers
| Name | Title |
|---|---|
| Mr. Joel Lewis | Pres, CEO & Director |
| Mr. Jack W. Callicutt CPA, CPA | CFO, Treasurer & Corp. Sec. |
| Dr. Pol F. Boudes M.D., Ph.D. | Chief Medical Officer |
| Robert Tritt | Gen. Counsel |
| Ms. Beth Knowles | Exec. Assistant & Officer Mang. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 207.6975 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2002-09-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |